Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), ...

Please provide your email address to receive an email when new articles are posted on . “The efficacy of SARS-CoV-2 vaccines in patients treated with immunosuppressive therapies remains uncertain. ...

Please provide your email address to receive an email when new articles are posted on . Under Medicare Part D drug benefits, the biosimilar infliximab-dyyb was only 18% less expensive than the ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

The study, with a small sample size, said most patients who take infliximab for more than 6 years report continued efficacy. Infliximab can be safe and effective as a long-term therapy in people with ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease (IBD). UC causes the colon and rectum to become inflamed and ulcerated. Inflammation is the process by which the body ...

Infliximab is an efficacious treatment for rheumatoid arthritis (RA). The recommended treatment schedule, however, is unsatisfactory in a substantial subset of patients. This study was an open-label ...

Infliximab plus the other antitumor necrosis factor (anti-TNF) agents, adalimumab and certolizumab, are effective in patients with Crohn's disease who have inflammatory-type disease. By the time ...

A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous ...